92.18 <%= Resources.Global.txtDown %>
Updated 18/01/2019
Change % -0.86% Stock price decreasing
Change -0.80 Stock price decreasing
Volume 363,230
High 94.00
Low 91.70
Open 93.52
ISIN BE0003818359
Prev close 92.98
# of shares 54.47M
Market cap 5,020.62M EUR

Market closed
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  92.18 1.3% Stock price increasing 5.8% Stock price increasing -1.6% Stock price decreasing 2.7% Stock price increasing 1.1% Stock price increasing
Powered by TradingView

News about Galapagos

  • English
  • Regulatory news

Company profile

Galapagos is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
19 January 2019 11:18:09
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190108.3 - EUROWEB6 - 2019-01-19 12:18:09 - 2019-01-19 11:18:09 - 1000 - Website: OKAY